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Clinical specimens and data 
Human formalin-fixed paraffin-embedded (FFPE) tumor specimens and tissue microarrays 
were obtained from Department of Pathology, National University Hospital (NUH, 
Singapore), as well as from patients who have undergone surgical resection at NUH. 
Germline DNA was obtained retrospectively from Pharmacogenetics DNA Bank and 
prospectively from patients with metastatic LUSC, HNSCC and NPC. All samples were 
processed with approval from National Healthcare Group’s Domain Specific Review Board 
(DSRB) Committee, and under the guideline of Institutional Review Board (IRB) at National 
University of Singapore (NUS, Singapore). Written informed consent was obtained in all 
cases from patients at time of enrolment.  
 
Mass spectrometry analysis.  
Samples were treated by in-gel digestion prior to MS analysis. In brief, samples were reduced 
in 10 mM DTT for 1h at 56°C followed by alkylation with 55mM iodoacetamide (Sigma) for 
45 min in the dark. Tryptic digest was performed in 50 mM ammonium bicarbonate buffer 
with 2 μg trypsin at 37°C overnight. Peptides were desalted on StageTips and analysed by 
nanoflow liquid chromatography on an EASY-nLC 1200 system coupled to a Q Exactive HF 
mass spectrometer (Thermo Fisher Scientific). Peptides were separated on a C18-reversed 
phase column (25 cm long, 75 μm inner diameter) packed in-house with ReproSil-Pur C18-
QAQ 1.9 μm resin (Dr Maisch). The column was mounted on an Easy Flex Nano Source and 
temperature controlled by a column oven (Sonation) at 40°C. A 105-min gradient from 2 to 
40% acetonitrile in 0.5% formic acid at a flow of 225 nl/min was used. Spray voltage was set 
to 2.4 kV. The Q Exactive HF was operated with a TOP20 MS/MS spectra acquisition 
method per MS full scan. MS scans were conducted with 60,000 and MS/MS scans with 
15,000 resolution. The raw files were processed with MaxQuant version 1.5.2.8 1 with preset 
standard settings for SILAC labelled samples and the re-quantify option was activated. 
Carbamidomethylation was set as fixed modification while methionine oxidation and protein 
N-acetylation were considered as variable modifications. Search results were filtered with a 
false discovery rate of 0.01.  
Cell viability assay. 
Approximately 3,000 cells/well in complete medium were seeded into clear-bottom black 96-
well plates 24 hours prior to drug treatment. Indicated compounds or rSema were added in 
serial dilution for 72 hours. The viability of cells were assayed using CellTiter-Glo 
luminescent reagent (Promega, #G7572). The luminescence signals were detected using 
TECAN Infinite M1000 pro multi-mode plate reader using an integration time of 1000 ms. 
The relative luminescence units from treated wells were normalized against the readings from 
DMSO control and expressed as percentage cell viability and presented as mean ± SD 
relative to DMSO-treated controls. IC50 values were calculated by curve-fitting using 
GraphPad Prism software, and expressed as mean value ± SD.  
 
RNAseq, EMT scoring, hierarchical clustering and pathway analysis. 
RNAseq and gene expression analyses were performed by Novogene. In brief, isogenic 
H2170 cell lines of wild type (WT) and METN375S genotypes were subjected to Illumina 
HiSeqTM2500 for RNA-seq. CASAVA v1.8 was used to convert the raw data to fastq files. 
Reads of low quality, adapter contamination, and reads with undetectable bases more than 
10% were removed, yielding 38,860,951 and 35,817,538 reads for WT and N375S 
respectively. Subsequently, we applied TopHat2 to map the reads to Ensembl human genome 
GRCh37. Only uniquely mapped reads for both WT 67,802,021 (87.24%) and N375S 
62,325,393 (87%) were retained for further analyses. The read counts were then converted to 
FPKM by normalizing the read counts by transcript length. Differentially expressed genes 
were identified using R package DESeq. Genes with adjusted p-value < 0.05 were deemed 
significant and selected for further analyses. Differentially expressed genes were subjected to 
GO enrichment analyses using GOseq and KEGG pathway enrichment analyses. Epithelial-
mesenchymal transition (EMT) enrichment score was computed using a signature and a two-
sample Kolmogorov-Smirnov-based method 2, with a negative score (<0) indicates epithelial-





Droplet digital Polymerase Chain Reaction (ddPCR) 
Genomic DNA (gDNA) was extracted from patient’s whole blood and plasma using 
QIAamp DNA mini kit (Qiagen, #51306) and QIAamp DNA FFPE Tissue kit (Qiagen, 
#56404) according to the manufacturer’s protocols. 20 ng of gDNA (or circulating DNA from 
100 µl of plasma) was used to perform ddPCR on Bio-Rad QX200TM Droplet Digital PCR 
system for detection of single nucleotide polymorphism of MET gene. Data was presented as 
hetero- or homozygous for MET (N375S) variant. Sequences of primers and probes are shown 
in Supplementary Table 3.  
 
Targeted exome sequencing 
 Amplicon-enriched targeted sequencing was performed and reported previously 3. 
Library preparation was conducted using GeneRead DNAseq Gene Human Lung Panel 
(Qiagen) according to manufacturer’s protocol, and exome sequencing was performed on 
Illumina HiSeq2000 Platform. The generated sequencing reads were subjected to variant 
calling by Genome Analysis Toolkit (GATK) from Broad Institute. Significantly mutated 
genes (P < 0.01) were identified by mapping to public database (dbSNP) and subjected to 
functional annotation with the COSMIC Database for detection of cancer-related mutations. 
Alterations on the MET, EGFR, KRAS, BRAF and ERBB2 genes were reported in this study. 
BioProject ID: PRJNA529714. 
 
Molecular Dynamics Simulations of MET Sema domain. 
The crystal structure of the Sema domain of wildtype MET (PDB ID: 4K3J) was used to 
explore the effects of the N375S mutation on the conformational effects. The missing 
loops/residues were modelled using Modeller 4. The structure of METN375S was generated by 
mutating Asn375 to Ser in the METwt structure using Pymol Program. These structures (of 
both METwt and METN375S) were subjected to molecular dynamics (MD) simulations using 
standard protocols and the program Amber18 5. To model possible modes of interactions 
between c-MET and HER2, we utilized the program CLICK to compare structural regions 
between two different proteins, irrespective of sequence similarity. This search was 
performed on the conformations of METwt and METN375S that were generated during the MD 
simulations. This search yielded a good conformational match between the region 
encompassing residues 364 to 385 in the Sema domain (the region colored as orange/magenta 
in the Supplementary Figure 12) with the structure of EGF in its complex with EGFR (PDB 
ID: 3LTF). The homology between the structures of EGFR and HER2 was used to guide the 
design of a complex between METwt and HER2 and between METN375S and HER2 and these 
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Supplementary Fig. 1: Mutations on MET gene in LUSC tissue specimens.
(A-B) Mutations on MET gene as sequenced by amplicon-enriched NGS. Oncoprint (A) and lollipop plot (B) 
demonstrating the distribution of missense/nonsense mutations across the 45 FFPE LUSC specimens.
(C) Tabulation of other genetic alterations (EGFR, BRAF) found in the METN375S-positive tumors. No 
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Supplementary Fig. 2: Polymorphic N375S variant enhances aggressive tumor phenotype in LUSC 
and HNSCC cells.
(A-D) Cell invasion and colony forming assays were performed on isogenic LUSC (Calu-1) and HNSCC 
(SCC13, UMSCC1) cells transfected with empty vector (EV), wild-type (METwt-tGFP) and N375S mutant 
(METN375S-tGFP). Immunoblots demonstrated expression levels of total and phosphorylated MET were shown 
(far right). β-actin was used as loading control.  
(A-B) For invasion assay, cells seeded in Matrigel invasion chambers were fixed and stained at 36 hours. (A) 
Representative images were shown. (B) The number of cells in four random microscopic fields (40×) were 
quantified for EV, METwt-tGFP and METN375S-tGFP cells and expressed as mean ± SD (n = 2-3). Two tailed 
Student’s t-test, *P < 0.05.
(C-D) Representative images of colony formation for each cell types, stained with MTT at assay endpoint 
(C). (D) The number of colonies were quantified for EV, METwt-tGFP and METN375S-tGFP cells and expressed 
as mean of triplicates ± SD (n > 3). 
(E) Immunoblot analysis of membrane and cytosolic fractions were performed for the CRISPR-edited, 
METN375S/N375S homozygous Calu-1 and H2170 cells cell lines. Pan-Cadherin (membrane) and α-tubulin 
(cytoplasmic) were used as loading controls.
(F-J) Cellular properties of METN375S/N375S cells were shown. Immunoblots demonstrated expression levels 
of total and phosphorylated MET were shown (right side of Figure S2H). β-actin was used as loading 
control.  (F) Representative images of the morphology of CRISPR-edited Calu-1 and H2170 clones (AA and 
AF). (G) Invasion assays were performed on the METN375S/N375S H2170 and Calu-1 clones. Representative 
images were shown. (H) The number of invaded cells in four random microscopic fields (40×) were 
quantified and expressed as mean ± SD (n = 3). (I) Invasion assays were performed on the METN375S/N375S
H2170 clones transfected with Scr or MET siRNA. Immunoblots demonstrated expression levels of total and 
phosphorylated MET were shown (bottom right). HSP90 was used as loading control.  Representative 
images were shown. (J) The number of invaded cells in four random microscopic fields (40×) were 
quantified and expressed as mean ± SD (n = 2). Two tailed Student’s t-test, *P < 0.05; **P < 0.01.
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Supplementary Fig. 3: Forced expression of METN375S does not impact susceptibility to MET 
inhibitors.
(A-H) Cell viability assays comparing sensitivities of isogenic H2170 cells to various TKIs. Cells were 
treated with increasing concentrations (0.01 to 30 µM) of cabozantinib (A), tepotinib (B), tivantinib (C), 
crizotinib (D), saracatinib (E), gefitinib (F), copanlisib (G), and trametinib (H) for 72 hours, and assayed 
with CellTiter-Glo reagents. Each dose-response curve showing the mean of triplicates ± SD for a 
representative experiment. Below, mean IC50 for the respective cell lines (n = 3). Two tailed Student’s t-test; 
*P < 0.05. 
(I) H2170 cells with ectopic expression of MET were treated with crizotinib or cabozantinib (1, 3, 10 µM). 
Immunoblots showing expression of the indicated targets in lysates of the isogenic H2170 EV, METwt-tGFP
and METN375S-tGFP cells. Cells were harvested 48 hours after treatment, and β-actin was used as loading 
control. 
(J-M) Efficacies of MET inhibitors were evaluated in xenograft models. Tumor growth of METwt (J) and 
METN375S (K) xenografts after treatment with crizotinib; and of METwt (L) and METN375S (M) xenografts 
after treatment with INC280 were expressed at mean ± SEM (n = 5). 
(O) H2170 METN375S-tGFP cells were treated with 1 µM crizotinib or 0.1% DMSO for 24hours, and subjected 
to cell invasion (n = 3), colony forming (n = 3), and cell migration (n = 2) assays. The wound closure 














Supplementary Fig. 4: Comparative transcriptomic of H2170 METwt and METN375S cells. 
(A) RNAseq was performed on total RNA harvested from isogenic H2170 METwt-tGFP and METN375S-tGFP 
cells. Volcano plot presentation of differentially expressed genes in the WT versus N375S cells. Red and 
blue points marked the up-regulated and down-regulated genes respectively in METN375S-tGFP cells. The x-
axis, log2(fold-changes) in expression; y-axis, -log10(q-value). 
(B) Heatmap comparing transcriptomic changes in epithelial-mesenchymal transition (EMT) gene signature 
between METwt-tGFP and METN375S-tGFP cells. EMT scores documenting the interplays between epithelial and 
























































Supplementary Fig. 5: Validating the specificity of METN375S-HER2 interaction.
(A) Interaction of ectopic MET and endogenous HER2 in H2170 METwt-tGFP and METN375S-tGFP cells was 
detected with immunoprecipitation and immunoblotting. Targets identified from SILAC experiment were 
validated (BAG3, RAPH1, ENO1 and RIT1) together with EGFR and Src. Representative blots of three 
independent experiments was shown (n = 3). 
(B) Specificity of METN375S interaction with HER2 was compared to other common MET variants. HEK293 
cells were transfected with 1 µg of either pCMV6-EV vector, MET-wt, E168D, S323G, N375S, R988C, or 
T1010I, together with pCMV6-ERBB2-DDK plasmid, for 24 hours. MET/HER2 interaction in HEK293 
cells was detected with immunoprecipitation and immunoblotting. Left, input controls and phosphorylated 




























































































Supplementary Fig. 6: Association of METN375S and HER2 in lung and breast carcinoma cells.
(A) Interaction of ectopic MET and endogenous HER2 in Calu-1 METwt-tGFP and METN375S-tGFP cells was 
detected with immunoprecipitation and immunoblotting. Left, input controls. Total MET and HER2 band 
intensities, normalized to input controls and relative to METwt, are shown below. Values represent 
average of three independent experiments.
(B-C) Detection of MET/HER2 co-localization (red) in EV, METwt-tGFP, and METN375S-tGFP cells with 
proximity ligation assay (PLA). Representative images were shown (B), with the PLA signals quantified 
(C) and expressed as number of signals/cell ± SD (n = 3). Scale bar, 20 µm.
(D-E) MET/HER2 interaction was validated in breast carcinoma cell lines, Sk-Br-3 (HER2+) (D) and 
MCF-7 (HER2-) (E), by immunoprecipitation and immunoblotting after transient transfection of 
pCMV6-MET (wt) and pCMV6-MET (N375S). 1 µg of plasmid was used per transfection. β-actin was 
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Supplementary Fig. 7: Forced expression of METN375S increases susceptibility to HER2 inhibitors.
(A-B) Cell viability assays showing sensitivities of isogenic H2170 cells to HER2 inhibitors. Cells were 
treated with increasing concentrations of lapatinib (A) and afatinib (B) for 72 hours, and assayed with 
CellTiter-Glo reagents. Each dose-response curve showing the mean of triplicates ± SD for a representative 
experiment. Below, mean IC50 for the respective cell lines (n = 3). Two tailed Student’s t-test; *P < 0.05. 
(C) H2170 cells with ectopic expression of MET were treated with crizotinib (1 µM), lapatinib (0.3 µM), 
afatinib (0.3 µM), or the indicated combinations. Immunoblots showing expression of the indicated targets 
in lysates of the isogenic H2170 EV, METwt-tGFP and METN375S-tGFP cells. Blots are representative of three 
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Supplementary Fig. 8: HER2 inhibition demonstrates anti-SCC efficacy in METN375S cells. 
(A-B) H2170 and Calu-1 cells were co-incubated with 10 µM of the indicated siRNA for 48 hours. 
Immunoblots showing changes on the indicated targets by MET and ERBB2 silencing in H2170 METN375S-
tGFP (A), Calu-1 METwt-tGFP and METN375S-tGFP cells (B). Blots are representative of two independent 
experiments. β-actin was used as loading control. 
(C-G) Anchorage-independent colony formation on isogenic H2170 METN375S-tGFP cells, treated with the 
indicated doses of crizotinib (C), lapatinib (D), trastuzumab (E), crizotinib/lapatinib (C/L) combination (F), 
or crizotinib/trastuzumab (C/T) combination (G) for 4 weeks. Representative images were shown for three 
independent experiments. 
(H-J) Efficacies of HER2 inhibitors were evaluated in xenograft models. Waterfall plots comparing tumor 
growth of METwt (H) and METN375S (I) xenografts after treatment with trastuzumab, pertuzumab, lapatinib 
and ASLAN001. (J) Immunohistochemistry staining showing the changes in p-HER2 after treatment with 
the respective inhibitors in and METN375S tumors. Representative images were shown. Scale bar, 50 µm. 
Right, expression of p-HER2 was quantified and expressed at mean of positive-staining/100 cells ± SD (n 
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Supplementary Fig. 9: HER2 inhibitors demonstrate anti-SCC properties in HNSCC cells but show 
lack of efficacy in HCC tumors.
(A) Cell viability assays showing sensitivities of NPC7 primary culture and SCC13 cell line to crizotinib, 
lapatinib and afatinib. Cells were treated with increasing concentrations of the compound for 72 hours, and 
assayed with CellTiter-Glo reagents. Each dose-response curve showing the mean of triplicates ± SD for a 
representative experiment. Below, mean IC50 for the respective cell lines (n = 3). Two tailed Student’s t-test; 
*P < 0.05.
(B-C) NCC-NPC7 (HNSCC primary cells) was treated with crizotinib (1 µM), lapatinib (1 µM), afatinib (1 
µM), or in the indicated combinations for 48 hours. Immunoblots showing changes on the indicated targets 
(B), while interaction of MET and HER2 in NCC-NPC7 cells, after treatment with vehicle (0.1% DMSO), 
MET inhibitor crizotinib (1 µM), HER2 inhibitor lapatinib (1 µM), or crizotinib/lapatinib combination, was 
detected with immunoprecipitation and immunoblotting (C). Total MET and HER2 band intensities, relative 
to vehicle treated group, are shown below. Values represent average of two independent experiments. Left, 
input controls. β-actin or IgG was used as loading control. 
(D-I) Efficacies of HER2 inhibitors were evaluated in patient-derived xenograft (PDX) models of 
hepatocellular carcinoma (HCC) expressing METN375S variant. Tumor growth of HCC13-0109 (D) and 
HCC26-0808B (E) xenografts after treatment with lapatinib, afatinib and trastuzumab were expressed at 
mean ± SEM (n = 5). Waterfall plots comparing tumor growth of HCC13-0109 (F) and HCC26-0808B (G). 
Immunohistochemistry staining showing the expression of p-MET and p-HER2 in HCC13-0109 (H) and 
HCC26-0808B (I). Representative images were shown. Scale bar, 50 µm.
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Supplementary Fig. 10: MET (N375S) status is positively correlating with p-HER2 expression in 
LUSC.
(A-F) Immunohistochemistry staining showing the expression of p-MET and p-HER2 in normal lung tissues 
(A), METwt LUSC tumors (n = 36) (B) and METN375S-positive LUSC tumors (n = 9) (C). Representative 
images were shown. Scale bar, 200 µm. Scoring of individual tumor was tabulated in Table S2, and plotted 
as bar charts for p-HER2 (D) and p-MET (E). The correlation between p-HER2 and p-MET associated with 
MET polymorphism was plotted (F). Data were expressed at mean ± SEM. Red dots indicating data points 
of METN375S-positive LUSC tumors (n = 9). Chi-square (and Fisher's exact) test was performed. (G) 
Relapse-free survival (RFS) of the 45 LUSC patients with their tumors stained with immunohistochemistry 
in Figure S8B and C were analyzed with Kaplan-Meier method and log rank test. RFS was measured from 
time of treatment/surgery to relapse. Subjects who have not reached study-defined endpoint were censored 








































Supplementary Fig. 11: Proposed mechanisms of METN375S tumors that attribute to aggressive SCC 
phenotype.
(Left) Wildtype MET requires binding of ligand (HGF) to be activated through receptor dimerization. 
(Right) Ligand-independent activation of HER2 requires receptor homodimerization, which is a common 
oncogene addicted pathway in HER2+ cells. The MET (N375S) polymorphism encodes for a polymorphic 
receptor which has reduced affinity to HGF, but acquires alternative binding to HER2 through interaction of 
the MET Sema domain and HER2 D4 domain, leading to tyrosine kinase phosphorylation and downstream 
activation. These attribute to the aggressive oncogenic phenotype in SCC cells as shown in our study. This 
oncogenic pathway could be effectively suppressed through inhibition of HER2 either by tyrosine kinase 





Supplementary Fig. 12: MET-N375S polymorphism is simulated to induce conformation changes to 
MET, and allowed for better interaction with HER2.
(A-B) A simulated conformation of the SEMA domain of (A) METWT and (B) METN375S; the structures are 
shown in green surface on the left and green ribbon on the right. The regions in the protein that undergo 
localized conformational changes upon mutation are highlighted in METWT (orange) and METN375S
(magenta) and the site of mutation is shown as spheres (N375 in METwt and S375 in METN375S). 
(C-D) A model of interaction between the SEMA domain and the extracellular domain of HER2 is shown as 
cartoon representation in (C) Sema domain of METwt in green complexed to HER2 in grey and (D) Sema
domain of METN375S in green complexed to HER2 in grey. The region of the Sema domain that undergoes 
localized conformational changes is highlighted in METwt (orange) and METN375S (magenta). A zoomed 
view of the site of interaction between the Sema domain and HER2 (grey surface) is shown. Black dashed 
lines indicate interactions between MET and HER2.
Supplementary Table 1















*Bold text indicates the N375S variation in both recombinant proteins.









Case 1 WT 1+ 0
Case 2 WT 0 0
Case 3 WT 0 0
Case 4 WT 0 0
Case 5 WT 0 0
Case 6 N375S 2+ 1+
Case 7 WT 0 0
Case 8 WT 0 0
Case 9 WT 1+ 0
Case 10 WT 2+ 1+
Case 11 WT 2+ 0
Case 12 WT 0 0
Case 13 WT 0 0
Case 14 WT 3+ 0
Case 15 N375S 3+ 2+
Case 16 WT 2+ 1+
Case 17 N375S 3+ 2+
Case 18 WT 0 0
Case 19 N375S 3+ 3+
Case 20 N375S 3+ 3+
Case 21 WT 1+ 1+
Case 22 WT 0 0
Case 23 WT 0 0
Case 24 WT 1+ 1+
Case 25 WT 2+ 2+
Case 26 WT 1+ 1+
Case 27 N375S 3+ 2+
Case 28 WT 0 0
Case 29 WT 0 0
Case 30 WT 1+ 1+
Case 31 WT 1+ 0
Case 32 N375S 3+ 2+
Case 33 WT 0 0
Case 34 WT 3+ 2+
Case 35 WT 2+ 1+
Case 36 WT 0 0
Case 37 N375S 2+ 2+
Case 38 WT 2+ 1+
Case 39 WT 0 0
Case 40 WT 0 1+
Case 41 N375S 3+ 2+
Case 42 WT 1+ 2+
Case 43 WT 0 0
Case 44 WT 0 0
Case 45 WT 0 1+
Supplementary Table 2: Scoring of p-HER2 and p-MET in tissue microarray of LUSC.
Supplementary Table 3
guide RNA sequences
Hs.Cas9.MET.1.AA /AltR1/rUrU rArCrU rUrCrU rUrGrA rCrGrG rUrCrC rArArA rGrUrU rUrUrA rGrArG rCrUrA rUrGrC rU/AltR2/
Hs.Cas9.MET.1.AF /AltR1/rArG rGrCrA rUrGrG rArCrA rUrArC rUrUrA rArUrG rGrUrU rUrUrA rGrArG rCrUrA rUrGrC rU/AltR2/) 
siRNA sequences
siMET sequence 1 5'-UGACAUUCUGGAUGGGUGUTG-3'
siMET sequence 2 5'-UUCGAUAUUCAUCACGGCGCG-3'
siERBB2 sequence 1 5'-UGUCUGUGCCGGUGCACACTT-3'
siERBB2 sequence 2 5'-UUCGUCUAAGAUUUCUUUGTT-3'





Supplementary Table 3: Nucleotide sequences for guide RNA, siRNA, ddPCR primers and probes.
